Evidence map›Paper›PMID 30325763›Full record

ArticleAIDS (London, England)2019

Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth.

Zabrina L Brumme, Hanwei Sudderuddin, Carrie Ziemniak, Katherine Luzuriaga, Bradley R Jones, Jeffrey B Joy, Coleen K Cunningham, Thomas Greenough, Deborah Persaud

Open access · greenAbstract read
In one paragraph

Article in AIDS (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby.
Hanwei SudderuddinFaculty of Health Sciences, Simon Fraser University, Burnaby.
Carrie ZiemniakJohns Hopkins University School of Medicine, Baltimore.
Katherine LuzuriagaUniversity of Massachusetts Medical School, Worcester, USA.
Bradley R JonesBC Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Jeffrey B JoyBC Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Coleen K CunninghamDuke University Medical Center, Durham, North Carolina, USA.
Thomas GreenoughUniversity of Massachusetts Medical School, Worcester, USA.
Deborah PersaudJohns Hopkins University School of Medicine, Baltimore.
Simon Fraser University · CAUniversity of British Columbia · CAUniversity of Massachusetts Chan Medical School · USDuke Medical Center · USJohns Hopkins University · USProtected Trust Services (United Kingdom) · GB

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1M
Early Antiretroviral Therapy and HIV Remission in Perinatal InfectionR01HD080474 · NICHD · JOHNS HOPKINS UNIVERSITY · PI BRYSON, YVONNE J., LUZURIAGA, KATHERINE F · 2014 to 2018
$6.5M
CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional CharacteristicsR01AI131798 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD · 2017 to 2021
$2.1M
Genetics, dynamics and fitness of the HIV-1 latent reservoirR21AI127029 · NIAID · SIMON FRASER UNIVERSITY · PI BROCKMAN, MARK ALAN, BRUMME, ZABRINA · 2018 to 2019
$300k
NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI131798NIAID NIH HHS R21 AI127029NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI106716NIAID NIH HHS UM1 AI126617NICHD NIH HHS HHSN275200800001INICHD NIH HHS R01 HD080474
6 · The paper itself

Abstract

objectiveTimely initiation of combination antiretroviral therapy (ART) limits latent HIV reservoir size and should also limit reservoir genetic complexity. However, the relationship between these two factors remains unclear, particularly among HIV-infected youth.

designRetrospective analysis of replication-competent latent HIV clones serially isolated by limiting-dilution culture from resting CD4 T-cell reservoirs from ART-suppressed, young adult participants of a historic phase I therapeutic vaccine trial (PACTG/IMPAACT-P1059).

methodsReplication-competent latent HIV clones isolated from resting CD4 T cells of four perinatally and 10 nonperinatally infected young adults (average 22 versus 6 years uncontrolled infection, respectively) were sequenced in Pol and Nef. Within-host HIV sequence datasets were characterized with respect to their genetic diversity and inferred immune escape mutation burden.

resultsAlthough participants were comparable in terms of sociodemographic and HIV sampling characteristics (e.g. on average, a mean 17 Pol sequences were recovered at five timepoints over up to 70 weeks) and the length of ART suppression at study entry (average 3 years), replication-competent HIV reservoir size, genetic diversity, immune escape mutation burden and variant complexity were significantly higher among the perinatally infected participants who experienced longer durations of uncontrolled viremia. Nevertheless, viral sequences inferred to retain susceptibility to host cellular immune responses were detected in all participants, irrespective of uncontrolled viremia duration.

conclusionHIV elimination in late-suppressed youth may be doubly challenged by larger and more genetically complex reservoirs. Strategies that integrate host and viral genetic complexity to achieve HIV remission or cure may merit consideration in such cases.

Indexed as

Genetic VariationVirus LatencyAdolescentAnti-Retroviral AgentsCD4-Positive T-LymphocytesDNA, ViralFemaleHIVHIV InfectionsHumansMalenef Gene Products, Human Immunodeficiency Viruspol Gene Products, Human Immunodeficiency VirusRetrospective StudiesSequence Analysis, DNAYoung AdultAnti-Retroviral AgentsDNA, Viralnef Gene Products, Human Immunodeficiency Viruspol Gene Products, Human Immunodeficiency Virus

Identifiers

PMID30325763
PMCPMC6298800
OpenAlexW2897459516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.